Immunomedics (IMMU) Reports Data on Sacituzumab Govitecan in Lung Cancer
Tweet Send to a Friend
Immunomedics, Inc., (Nasdaq: IMMU) today announced that 33% of patients with small cell lung cancer (SCLC) and 31% with non-small ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
